25 XP   0   0   10

Cyclerion Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Cyclerion together

PenkeI guess you are interested in Cyclerion Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cyclerion Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cyclerion Therapeutics Inc

I send you an email if I find something interesting about Cyclerion Therapeutics Inc.

Quick analysis of Cyclerion (30 sec.)










What can you expect buying and holding a share of Cyclerion? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.17
Expected worth in 1 year
$4.47
How sure are you?
42.3%

+ What do you gain per year?

Total Gains per Share
$0.31
Return On Investment
10.1%

For what price can you sell your share?

Current Price per Share
$3.05
Expected price per share
$2.8 - $3.98
How sure are you?
50%

1. Valuation of Cyclerion (5 min.)




Live pricePrice per Share (EOD)

$3.05

Intrinsic Value Per Share

$-60.48 - $-69.70

Total Value Per Share

$-56.32 - $-65.53

2. Growth of Cyclerion (5 min.)




Is Cyclerion growing?

Current yearPrevious yearGrowGrow %
How rich?$11.2m$22.3m-$14m-168.9%

How much money is Cyclerion making?

Current yearPrevious yearGrowGrow %
Making money-$1.2m-$10.9m$9.6m757.5%
Net Profit Margin0.0%-6,182.5%--

How much money comes from the company's main activities?

3. Financial Health of Cyclerion (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#663 / 1011

Most Revenue
#1004 / 1011

Most Profit
#255 / 1011

Most Efficient
#447 / 1011

What can you expect buying and holding a share of Cyclerion? (5 min.)

Welcome investor! Cyclerion's management wants to use your money to grow the business. In return you get a share of Cyclerion.

What can you expect buying and holding a share of Cyclerion?

First you should know what it really means to hold a share of Cyclerion. And how you can make/lose money.

Speculation

The Price per Share of Cyclerion is $3.05. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cyclerion.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cyclerion, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.17. Based on the TTM, the Book Value Change Per Share is $0.08 per quarter. Based on the YOY, the Book Value Change Per Share is $0.69 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cyclerion.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.63-20.5%-0.49-15.9%-0.88-28.8%-3.99-130.7%-4.34-142.2%
Usd Book Value Change Per Share-0.58-19.2%0.082.5%0.6922.5%0.237.5%0.165.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.58-19.2%0.082.5%0.6922.5%0.237.5%0.165.3%
Usd Price Per Share3.35-2.83-0.79-4.55-3.50-
Price to Earnings Ratio-1.34--0.44--0.58--0.49--0.37-
Price-to-Total Gains Ratio-5.73-1.10--2.58--0.76--0.76-
Price to Book Ratio0.80-1.00-1.17-0.34-0.26-
Price-to-Total Gains Ratio-5.73-1.10--2.58--0.76--0.76-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.05
Number of shares327
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.080.23
Usd Total Gains Per Share0.080.23
Gains per Quarter (327 shares)25.2274.35
Gains per Year (327 shares)100.87297.42
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10101910297287
202021920595584
303032930892881
40403394011901178
50504495014871475
60605596017851772
70706697020822069
80807798023792366
90908899026772663
10010091000029742960

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%1.023.02.03.8%1.023.02.03.8%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%8.012.00.040.0%11.015.00.042.3%11.015.00.042.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.026.00.0%0.00.026.00.0%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%8.012.00.040.0%11.015.00.042.3%11.015.00.042.3%

Fundamentals of Cyclerion

About Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 05:42:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cyclerion Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cyclerion earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cyclerion to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cyclerion Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-6,182.5%+6,182.5%
TTM-5Y-4,846.0%+4,846.0%
5Y-4,846.0%10Y-3,727.7%-1,118.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--196.1%+196.1%
TTM--211.9%+211.9%
YOY-6,182.5%-277.7%-5,904.8%
5Y-4,846.0%-432.9%-4,413.1%
10Y-3,727.7%-599.3%-3,128.4%
1.1.2. Return on Assets

Shows how efficient Cyclerion is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cyclerion to the Biotechnology industry mean.
  • -12.7% Return on Assets means that Cyclerion generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cyclerion Therapeutics Inc:

  • The MRQ is -12.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.7%TTM-15.9%+3.2%
TTM-15.9%YOY-36.4%+20.5%
TTM-15.9%5Y-38.1%+22.3%
5Y-38.1%10Y-37,224.0%+37,185.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.7%-13.3%+0.6%
TTM-15.9%-12.7%-3.2%
YOY-36.4%-11.8%-24.6%
5Y-38.1%-14.0%-24.1%
10Y-37,224.0%-15.9%-37,208.1%
1.1.3. Return on Equity

Shows how efficient Cyclerion is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cyclerion to the Biotechnology industry mean.
  • -15.0% Return on Equity means Cyclerion generated $-0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cyclerion Therapeutics Inc:

  • The MRQ is -15.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -52.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.0%TTM-52.5%+37.5%
TTM-52.5%YOY-54.3%+1.7%
TTM-52.5%5Y-35.3%-17.2%
5Y-35.3%10Y-27.2%-8.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.0%-16.9%+1.9%
TTM-52.5%-16.0%-36.5%
YOY-54.3%-15.1%-39.2%
5Y-35.3%-19.7%-15.6%
10Y-27.2%-20.5%-6.7%

1.2. Operating Efficiency of Cyclerion Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cyclerion is operating .

  • Measures how much profit Cyclerion makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cyclerion to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cyclerion Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-6,214.0%+6,214.0%
TTM-5Y-5,066.9%+5,066.9%
5Y-5,066.9%10Y-3,897.6%-1,169.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--290.9%+290.9%
TTM--224.4%+224.4%
YOY-6,214.0%-288.3%-5,925.7%
5Y-5,066.9%-479.5%-4,587.4%
10Y-3,897.6%-625.2%-3,272.4%
1.2.2. Operating Ratio

Measures how efficient Cyclerion is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cyclerion Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY62.759-62.759
TTM-5Y50.571-50.571
5Y50.57110Y38.901+11.670
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.110-3.110
TTM-3.266-3.266
YOY62.7593.783+58.976
5Y50.5715.657+44.914
10Y38.9017.783+31.118

1.3. Liquidity of Cyclerion Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cyclerion is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.85 means the company has $3.85 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cyclerion Therapeutics Inc:

  • The MRQ is 3.847. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.651. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ3.847TTM2.651+1.195
TTM2.651YOY3.053-0.402
TTM2.6515Y3.995-1.344
5Y3.99510Y3.083+0.912
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8473.905-0.058
TTM2.6514.212-1.561
YOY3.0535.337-2.284
5Y3.9956.062-2.067
10Y3.0836.401-3.318
1.3.2. Quick Ratio

Measures if Cyclerion is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cyclerion to the Biotechnology industry mean.
  • A Quick Ratio of 3.63 means the company can pay off $3.63 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cyclerion Therapeutics Inc:

  • The MRQ is 3.629. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.406. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.629TTM2.406+1.223
TTM2.406YOY2.911-0.505
TTM2.4065Y3.820-1.414
5Y3.82010Y2.939+0.882
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.6293.572+0.057
TTM2.4064.001-1.595
YOY2.9115.364-2.453
5Y3.8206.009-2.189
10Y2.9396.287-3.348

1.4. Solvency of Cyclerion Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cyclerion assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cyclerion to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.16 means that Cyclerion assets are financed with 15.6% credit (debt) and the remaining percentage (100% - 15.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cyclerion Therapeutics Inc:

  • The MRQ is 0.156. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.364. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.156TTM0.364-0.208
TTM0.364YOY0.312+0.053
TTM0.3645Y0.431-0.067
5Y0.43110Y0.906-0.475
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1560.336-0.180
TTM0.3640.334+0.030
YOY0.3120.271+0.041
5Y0.4310.366+0.065
10Y0.9060.389+0.517
1.4.2. Debt to Equity Ratio

Measures if Cyclerion is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cyclerion to the Biotechnology industry mean.
  • A Debt to Equity ratio of 18.5% means that company has $0.18 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cyclerion Therapeutics Inc:

  • The MRQ is 0.185. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.811. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.185TTM0.811-0.627
TTM0.811YOY0.473+0.339
TTM0.8115Y0.623+0.188
5Y0.62310Y0.479+0.144
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1850.382-0.197
TTM0.8110.397+0.414
YOY0.4730.341+0.132
5Y0.6230.432+0.191
10Y0.4790.465+0.014

2. Market Valuation of Cyclerion Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cyclerion generates.

  • Above 15 is considered overpriced but always compare Cyclerion to the Biotechnology industry mean.
  • A PE ratio of -1.34 means the investor is paying $-1.34 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cyclerion Therapeutics Inc:

  • The EOD is -1.220. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.340. Based on the earnings, the company is expensive. -2
  • The TTM is -0.436. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.220MRQ-1.340+0.120
MRQ-1.340TTM-0.436-0.904
TTM-0.436YOY-0.582+0.146
TTM-0.4365Y-0.486+0.050
5Y-0.48610Y-0.374-0.112
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.220-2.262+1.042
MRQ-1.340-2.599+1.259
TTM-0.436-2.674+2.238
YOY-0.582-4.133+3.551
5Y-0.486-6.258+5.772
10Y-0.374-6.171+5.797
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cyclerion Therapeutics Inc:

  • The EOD is -1.341. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.473. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.570. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.341MRQ-1.473+0.132
MRQ-1.473TTM-0.570-0.903
TTM-0.570YOY-0.624+0.054
TTM-0.5705Y-0.601+0.031
5Y-0.60110Y-0.463-0.139
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.341-2.913+1.572
MRQ-1.473-3.275+1.802
TTM-0.570-3.508+2.938
YOY-0.624-5.620+4.996
5Y-0.601-8.306+7.705
10Y-0.463-8.854+8.391
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cyclerion is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.80 means the investor is paying $0.80 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cyclerion Therapeutics Inc:

  • The EOD is 0.732. Based on the equity, the company is cheap. +2
  • The MRQ is 0.804. Based on the equity, the company is cheap. +2
  • The TTM is 0.998. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.732MRQ0.804-0.072
MRQ0.804TTM0.998-0.194
TTM0.998YOY1.169-0.171
TTM0.9985Y0.339+0.659
5Y0.33910Y0.261+0.078
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.7321.858-1.126
MRQ0.8042.090-1.286
TTM0.9982.091-1.093
YOY1.1692.866-1.697
5Y0.3393.488-3.149
10Y0.2613.836-3.575
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cyclerion Therapeutics Inc.

3.1. Institutions holding Cyclerion Therapeutics Inc

Institutions are holding 41.341% of the shares of Cyclerion Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Slate Path Capital LP13.20540.026635788000
2023-12-31MFN Partners Management, LP6.25290.018316946000
2023-12-31Tyndall Management, LLC6.06731001644291671711.3173
2023-12-31TYNDALL CAPITAL PARTNERS L P6.06731001644291671711.3173
2023-12-31FMR Inc6.0090162849-1700-1.0331
2023-12-31Artal Group S A5.12730.01551389555520.3988
2023-12-31Geode Capital Management, LLC1.15340312595101.6586
2023-12-31Vanguard Group Inc0.8668023490-17041-42.0444
2023-12-31BlackRock Inc0.6335017169-831-4.6167
2023-12-31UBS Group AG0.0822022281952707.2464
2023-12-31Morgan Stanley - Brokerage Accounts0.02580698-125-15.1883
2023-12-31Group One Trading, LP0.0199054000
2023-12-31Royal Bank of Canada0.01220330-582-63.8158
2023-12-31Advisor Group Holdings, Inc.0.00690187-1-0.5319
2023-12-31Wells Fargo & Co0.000601517.1429
2023-12-31Northwestern Mutual Wealth Management Co00100
2023-09-30CapTrust Financial Advisors000-14631-100
2023-12-31Acadian Asset Management LLC000-2236-100
2023-09-30JANE STREET GROUP, LLC000-13364-100
2023-12-31Rhumbline Advisers000-1-100
Total 45.5305200.06041233919-14063-1.1%

3.2. Funds holding Cyclerion Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Fidelity Select Biotechnology1.54470.00274186400
2024-01-31Fidelity Growth Compy Commingled Pl O1.07450.0001291206352.2292
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.86680.00012349000
2024-01-31Fidelity Growth Company Fund0.77140.000120907-198-0.9382
2024-02-29Fidelity Nasdaq Composite ETF0.50960.000713812-28-0.2023
2024-01-31Fidelity Extended Market Index0.3630.0001983900
2024-01-31Fidelity Growth Company K60.35180.00029534-237-2.4255
2023-09-30BlackRock Extended Mkt Composite0.12690.0001343900
2023-12-31BlackRock Extended Equity Market K0.11070.00013000-6-0.1996
2024-01-31Fidelity Series Growth Company0.09260.00012510-200-7.3801
2024-01-31Fidelity Nasdaq Composite Index0.09250.0001250800
2024-01-31Fidelity Series Total Market Index0.08580232500
2024-01-31Fidelity Total Market Index0.08340226000
2023-12-31NT Ext Equity Mkt Idx Fd - L0.06350.0001172200
2023-12-31Northern Trust Extended Eq Market Idx0.06350.0001172200
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.06220.0001168600
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.050.0001135430.2221
2024-01-31Spartan Total Market Index Pool E0.0282076300
2024-01-31Spartan Extended Market Index Pool E0.01920.000151900
2024-02-29State St US Extended Mkt Indx NL Cl C0.01860.000150300
Total 6.37890.005172877-310.0%

3.3. Insider Transactions

Insiders are holding 20.77% of the shares of Cyclerion Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-08-09Terrance McguireSELL83.4

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cyclerion Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.5850.077-858%0.686-185%0.227-357%0.160-465%
Book Value Per Share--4.1653.066+36%1.418+194%13.134-68%9.613-57%
Current Ratio--3.8472.651+45%3.053+26%3.995-4%3.083+25%
Debt To Asset Ratio--0.1560.364-57%0.312-50%0.431-64%0.906-83%
Debt To Equity Ratio--0.1850.811-77%0.473-61%0.623-70%0.479-61%
Dividend Per Share----0%-0%-0%-0%
Eps---0.625-0.485-22%-0.878+40%-3.986+538%-4.339+594%
Free Cash Flow Per Share---0.569-1.960+245%-0.843+48%-3.854+578%-4.418+677%
Free Cash Flow To Equity Per Share---0.569-1.496+163%-0.841+48%1.222-147%1.018-156%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.923+8%
Intrinsic Value_10Y_max---69.697--------
Intrinsic Value_10Y_min---60.485--------
Intrinsic Value_1Y_max---7.208--------
Intrinsic Value_1Y_min---7.080--------
Intrinsic Value_3Y_max---21.487--------
Intrinsic Value_3Y_min---20.516--------
Intrinsic Value_5Y_max---35.560--------
Intrinsic Value_5Y_min---33.020--------
Market Cap8265805.000-10%9078835.0007672225.348+18%27807524.205-67%28842492.911-69%22186533.008-59%
Net Profit Margin----0%-61.8250%-48.4600%-37.2770%
Operating Margin----0%-62.1400%-50.6690%-38.9760%
Operating Ratio----0%62.759-100%50.571-100%38.901-100%
Pb Ratio0.732-10%0.8040.998-19%1.169-31%0.339+137%0.261+208%
Pe Ratio-1.220+9%-1.340-0.436-67%-0.582-57%-0.486-64%-0.374-72%
Price Per Share3.050-10%3.3502.831+18%0.794+322%4.550-26%3.500-4%
Price To Free Cash Flow Ratio-1.341+9%-1.473-0.570-61%-0.624-58%-0.601-59%-0.463-69%
Price To Total Gains Ratio-5.215+9%-5.7281.102-620%-2.579-55%-0.762-87%-0.762-87%
Quick Ratio--3.6292.406+51%2.911+25%3.820-5%2.939+24%
Return On Assets---0.127-0.159+25%-0.364+188%-0.381+201%-372.240+293781%
Return On Equity---0.150-0.525+250%-0.543+262%-0.353+135%-0.272+81%
Total Gains Per Share---0.5850.077-858%0.686-185%0.227-357%0.160-465%
Usd Book Value--11288000.0008309000.000+36%22342750.000-49%48687350.000-77%35762702.951-68%
Usd Book Value Change Per Share---0.5850.077-858%0.686-185%0.227-357%0.160-465%
Usd Book Value Per Share--4.1653.066+36%1.418+194%13.134-68%9.613-57%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.625-0.485-22%-0.878+40%-3.986+538%-4.339+594%
Usd Free Cash Flow---1541000.000-5311250.000+245%-10152750.000+559%-14075200.000+813%-14709423.077+855%
Usd Free Cash Flow Per Share---0.569-1.960+245%-0.843+48%-3.854+578%-4.418+677%
Usd Free Cash Flow To Equity Per Share---0.569-1.496+163%-0.841+48%1.222-147%1.018-156%
Usd Market Cap8265805.000-10%9078835.0007672225.348+18%27807524.205-67%28842492.911-69%22186533.008-59%
Usd Price Per Share3.050-10%3.3502.831+18%0.794+322%4.550-26%3.500-4%
Usd Profit---1694000.000-1271750.000-25%-10905500.000+544%-15058200.000+789%-16016000.000+845%
Usd Revenue----0%480500.000-100%602300.000-100%463307.692-100%
Usd Total Gains Per Share---0.5850.077-858%0.686-185%0.227-357%0.160-465%
 EOD+3 -5MRQTTM+20 -9YOY+21 -105Y+14 -1710Y+17 -15

4.2. Fundamental Score

Let's check the fundamental score of Cyclerion Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.220
Price to Book Ratio (EOD)Between0-10.732
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.629
Current Ratio (MRQ)Greater than13.847
Debt to Asset Ratio (MRQ)Less than10.156
Debt to Equity Ratio (MRQ)Less than10.185
Return on Equity (MRQ)Greater than0.15-0.150
Return on Assets (MRQ)Greater than0.05-0.127
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Cyclerion Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.395
Ma 20Greater thanMa 503.184
Ma 50Greater thanMa 1003.128
Ma 100Greater thanMa 2003.180
OpenGreater thanClose3.210
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets13,374
Total Liabilities2,086
Total Stockholder Equity11,288
 As reported
Total Liabilities 2,086
Total Stockholder Equity+ 11,288
Total Assets = 13,374

Assets

Total Assets13,374
Total Current Assets8,024
Long-term Assets5,350
Total Current Assets
Cash And Cash Equivalents 7,571
Other Current Assets 11
Total Current Assets  (as reported)8,024
Total Current Assets  (calculated)7,582
+/- 442
Long-term Assets
Property Plant Equipment 126
Long Term Investments 5,350
Long-term Assets  (as reported)5,350
Long-term Assets  (calculated)5,476
+/- 126

Liabilities & Shareholders' Equity

Total Current Liabilities2,086
Long-term Liabilities0
Total Stockholder Equity11,288
Total Current Liabilities
Accounts payable 1,198
Other Current Liabilities 888
Total Current Liabilities  (as reported)2,086
Total Current Liabilities  (calculated)2,086
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Retained Earnings -264,417
Accumulated Other Comprehensive Income -12
Other Stockholders Equity 275,717
Total Stockholder Equity (as reported)11,288
Total Stockholder Equity (calculated)11,288
+/-0
Other
Cash and Short Term Investments 7,571
Common Stock Shares Outstanding 2,474
Liabilities and Stockholders Equity 13,374
Net Debt -7,571
Net Invested Capital 11,288
Net Working Capital 5,938



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-31
> Total Assets 
3,875
5,470
3
6,662
6,756
7,401
9,773
235,503
209,704
186,478
140,030
128,038
131,402
115,378
99,967
75,732
67,742
59,331
46,525
35,213
25,053
18,079
11,456
10,097
15,214
13,374
13,37415,21410,09711,45618,07925,05335,21346,52559,33167,74275,73299,967115,378131,402128,038140,030186,478209,704235,5039,7737,4016,7566,66235,4703,875
   > Total Current Assets 
0
0
0
1,259
862
879
939
144,693
120,706
101,197
70,126
59,562
70,124
58,501
44,446
72,989
63,682
55,457
42,836
31,679
21,656
14,820
8,335
7,113
9,864
8,024
8,0249,8647,1138,33514,82021,65631,67942,83655,45763,68272,98944,44658,50170,12459,56270,126101,197120,706144,6939398798621,259000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
141,030
117,034
94,895
67,096
56,462
66,840
54,395
41,429
70,390
62,503
53,961
41,125
30,323
20,405
13,382
7,169
5,641
9,108
7,571
7,5719,1085,6417,16913,38220,40530,32341,12553,96162,50370,39041,42954,39566,84056,46267,09694,895117,034141,0300000000
       Net Receivables 
0
0
0
0
0
0
0
1,857
1,440
1,474
1,026
751
400
127
0
0
158
100
227
227
227
96
96
0
0
0
0009696227227227100158001274007511,0261,4741,4401,8570000000
       Inventory 
0
0
0
0
0
0
0
1,778
2,164
1,966
1,868
2,260
1,218
816
0
0
562
928
1,007
647
536
805
567
0
0
0
0005678055366471,007928562008161,2182,2601,8681,9662,1641,7780000000
   > Long-term Assets 
0
0
0
0
0
6,522
8,834
90,810
88,998
85,281
69,904
68,476
61,278
56,877
55,521
2,743
4,060
3,874
3,689
3,534
3,397
3,259
3,121
2,984
5,350
5,350
5,3505,3502,9843,1213,2593,3973,5343,6893,8744,0602,74355,52156,87761,27868,47669,90485,28188,99890,8108,8346,52200000
       Property Plant Equipment 
3,600
4,131
2
5,346
5,858
6,497
8,815
83,084
81,272
79,750
63,854
62,093
54,576
50,267
49,003
153
1,561
1,467
1,373
1,310
1,264
1,218
1,171
1,125
0
126
12601,1251,1711,2181,2641,3101,3731,4671,56115349,00350,26754,57662,09363,85479,75081,27283,0848,8156,4975,8585,34624,1313,600
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,350
5,350
5,3505,350000000000000000000000000
       Other Assets 
0
80
0
57
36
25
19
7,726
7,726
5,531
6,050
6,383
6,702
50,012
6,518
2,590
2,499
2,407
2,316
2,224
2,133
2,041
0
0
0
0
00002,0412,1332,2242,3162,4072,4992,5906,51850,0126,7026,3836,0505,5317,7267,726192536570800
> Total Liabilities 
10,636
14,037
7
16,682
14,876
17,846
17,525
94,313
90,507
88,749
58,490
61,937
56,048
55,885
51,534
10,510
11,355
11,085
9,491
9,852
8,529
7,627
7,531
4,947
2,341
2,086
2,0862,3414,9477,5317,6278,5299,8529,49111,08511,35510,51051,53455,88556,04861,93758,49088,74990,50794,31317,52517,84614,87616,682714,03710,636
   > Total Current Liabilities 
10,636
14,037
7
16,682
14,876
17,846
17,473
21,916
19,096
18,249
11,435
15,645
16,262
16,952
13,467
10,510
11,355
11,085
9,491
9,852
8,529
7,627
7,531
4,947
2,341
2,086
2,0862,3414,9477,5317,6278,5299,8529,49111,08511,35510,51013,46716,95216,26215,64511,43518,24919,09621,91617,47317,84614,87616,682714,03710,636
       Short-term Debt 
0
0
0
0
0
0
0
866
3,250
3,420
2,668
6,296
6,642
6,802
6,894
3,509
3,509
0
0
0
0
0
0
0
0
0
0000000003,5093,5096,8946,8026,6426,2962,6683,4203,2508660000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
3,509
3,509
3,509
3,509
3,509
3,509
0
0
0
0
0
0
0
0
0
0000000003,5093,5093,5093,5093,5093,50900000000000
       Accounts payable 
1,410
1,802
1
3,655
2,943
2,781
5,671
8,783
5,005
3,311
1,522
2,588
1,855
1,435
1,095
1,386
1,174
1,828
2,519
2,767
1,645
2,970
3,925
1,864
814
1,198
1,1988141,8643,9252,9701,6452,7672,5191,8281,1741,3861,0951,4351,8552,5881,5223,3115,0058,7835,6712,7812,9433,65511,8021,410
       Other Current Liabilities 
9,226
12,235
1
1,337
5
15,065
11,802
115
36
404
727
579
343
176
375
222
833
9,257
6,972
7,085
6,884
4,657
3,606
3,083
1,527
888
8881,5273,0833,6064,6576,8847,0856,9729,2578332223751763435797274043611511,80215,06551,337112,2359,226
   > Long-term Liabilities 
0
0
0
0
0
0
52
72,397
71,411
70,500
47,055
46,292
39,786
38,933
38,067
0
0
1,828
2,519
2,767
1,645
2,970
3,925
0
0
0
0003,9252,9701,6452,7672,5191,8280038,06738,93339,78646,29247,05570,50071,41172,39752000000
       Other Liabilities 
0
0
0
0
0
0
52
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000052000000
> Total Stockholder Equity
0
0
-8,567
-10,020
-8,120
-10,445
-7,752
141,190
119,197
97,729
81,540
66,101
75,354
59,493
48,433
65,222
56,387
48,246
37,034
25,361
16,524
10,452
3,925
5,150
12,873
11,288
11,28812,8735,1503,92510,45216,52425,36137,03448,24656,38765,22248,43359,49375,35466,10181,54097,729119,197141,190-7,752-10,445-8,120-10,020-8,56700
   Common Stock0000000000000000000-7,752-10,445-8,120-10,020-400
   Retained Earnings Total Equity000-266,1080000000-176,828-163,429-144,201-125,389-105,855-85,627-59,572-32,2540000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
-15,491
-16,017
-4
1
-20
-18
-30
-27
-27
-27
-26
-26
-23
-24
-25
-28
-20
-19
-16
-18
-12
-12-18-16-19-20-28-25-24-23-26-26-27-27-27-30-18-201-4-16,017-15,49100000
   Capital Surplus 
0
0
0
0
0
0
0
173,448
178,768
183,376
187,413
191,520
219,582
222,949
225,288
0
0
0
0
0
0
0
270,052
0
0
0
000270,0520000000225,288222,949219,582191,520187,413183,376178,768173,4480000000
   Treasury Stock00000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
5,046
8,265
173,448
178,768
183,376
187,413
191,520
219,582
222,949
225,288
258,258
260,713
263,345
265,112
266,828
268,490
269,626
270,052
275,455
275,614
275,717
275,717275,614275,455270,052269,626268,490266,828265,112263,345260,713258,258225,288222,949219,582191,520187,413183,376178,768173,4488,2655,04600000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-9,647
Operating Income-9,647-9,647
 
Operating Expense (+$)
Research Development1,515
Selling General Administrative8,132
Selling And Marketing Expenses0
Operating Expense9,6479,647
 
Net Interest Income (+$)
Interest Income358
Interest Expense-0
Other Finance Cost-31
Net Interest Income389
 
Pretax Income (+$)
Operating Income-9,647
Net Interest Income389
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-12,593-6,701
EBIT - interestExpense = 0
-12,593
-21,015
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-12,593
Earnings Before Interest and Taxes (EBITDA)-9,647
 
After tax Income (+$)
Income Before Tax-12,593
Tax Provision-0
Net Income From Continuing Ops-41,054-12,593
Net Income-21,015
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses9,647
Total Other Income/Expenses Net-2,946-389
 

Technical Analysis of Cyclerion
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cyclerion. The general trend of Cyclerion is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cyclerion's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cyclerion Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 3.5475 < 3.7 < 3.98.

The bearish price targets are: 2.92 > 2.8 > 2.8.

Tweet this
Cyclerion Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cyclerion Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cyclerion Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cyclerion Therapeutics Inc. The current macd is 0.02984572.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cyclerion price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Cyclerion. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Cyclerion price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Cyclerion Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartCyclerion Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cyclerion Therapeutics Inc. The current adx is 17.82.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cyclerion shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Cyclerion Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cyclerion Therapeutics Inc. The current sar is 3.62067298.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Cyclerion Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cyclerion Therapeutics Inc. The current rsi is 46.40. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Cyclerion Therapeutics Inc Daily Relative Strength Index (RSI) ChartCyclerion Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cyclerion Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cyclerion price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Cyclerion Therapeutics Inc Daily Stochastic Oscillator ChartCyclerion Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cyclerion Therapeutics Inc. The current cci is -70.30498449.

Cyclerion Therapeutics Inc Daily Commodity Channel Index (CCI) ChartCyclerion Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cyclerion Therapeutics Inc. The current cmo is -12.23858483.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cyclerion Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartCyclerion Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cyclerion Therapeutics Inc. The current willr is -78.81355932.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cyclerion is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Cyclerion Therapeutics Inc Daily Williams %R ChartCyclerion Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cyclerion Therapeutics Inc. The current atr is 0.29038306.

Cyclerion Therapeutics Inc Daily Average True Range (ATR) ChartCyclerion Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cyclerion Therapeutics Inc. The current obv is 585,325.

Cyclerion Therapeutics Inc Daily On-Balance Volume (OBV) ChartCyclerion Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cyclerion Therapeutics Inc. The current mfi is 79.39.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Cyclerion Therapeutics Inc Daily Money Flow Index (MFI) ChartCyclerion Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cyclerion Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-12MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-13BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-19BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Cyclerion Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cyclerion Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.395
Ma 20Greater thanMa 503.184
Ma 50Greater thanMa 1003.128
Ma 100Greater thanMa 2003.180
OpenGreater thanClose3.210
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cyclerion with someone you think should read this too:
  • Are you bullish or bearish on Cyclerion? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cyclerion? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cyclerion Therapeutics Inc

I send you an email if I find something interesting about Cyclerion Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cyclerion Therapeutics Inc.

Receive notifications about Cyclerion Therapeutics Inc in your mailbox!